An industry for healthy lives

Vaccines Europe represents all the major vaccine companies operating in Europe which undertake 79% of their global production and more than 50% of their global research projects in the region.

Access to vaccines

Immunisation is one the major public health achievements of the 20th century. Indeed, vaccination campaigns around the world have been responsible for the eradication of smallpox and have significantly reduced the burden of other diseases.

Population access to vaccines is essential to decrease the number of cases of common, dangerous, handicapping and potentially fatal vaccine preventable diseases. For this reason, Vaccines Europe is committed to ensuring fast and wider access of EU populations to vaccines and aims to enable better protection of health throughout life of individuals and the wider community both with existing vaccines and those on development.

Population access to new vaccines

A retrospective study conducted by Vaccines Europe highlights that time from registration to population access to new vaccines can take considerable time in European countries. In particular, the study shows that the median access time to new vaccines was 6.4 years post marketing authorization. Read more…

 

Best practices for vaccine market access

Vaccines Europe is conducting a project which objective is to revise and compare NITAGs’ policies and decision-making processes for vaccine market access in both EU and non-EU countries. Read more…

 

Health Technology Assessment for vaccines

In the light of the current discussions at EU level on HTA, Vaccines Europe is conducting a project that seeks to identify vaccine-specific HTA related issues and conduct a gap analysis to understand the reason why vaccine-specific issues might not be addressed in current guidelines. Read more…